Product Images Zontivity
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Zontivity NDC 66992-208 by Wraser Pharmaceuticals, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1 - zontivity 01
Chemical Structure - zontivity 02
Figure 2 - zontivity 03
This appears to be a table containing information regarding the impact of intrinsic factors on Moan Effoct and 90% €1 Dose Adjustment. The factors mentioned include Age, Gender, Race, Renal impairment, and Hepatic impairment. The table provides recommendations on whether or not dose adjustment is needed based on the factors present. The last row suggests the recommended use of the tool or information. There appears to be a reference to a "Ghanga Ratio to Refrenca" but without further context, it is unclear what this means.*
Figure 3 - zontivity 04
This is a description of different types of medication. It includes antacids, specifically Gaviscon Extra Strength in liquid form, a proton pump inhibitor called Pantoprazole at 0mg, and Prasugrel at 10mg. Additionally, there is mention of a "Moan Effectand 30% C1 Dose Adjustment" and advice to avoid certain combinations of medication. The numbers listed at the bottom do not provide clear context.*
Figure 4 - zontivity 05
This text provides information on dose adjustment requirements for drugs interacting with certain enzymes and substrates. Specifically, the chart shows the mean effect and 90% confidence interval for interacting drugs, with dosage adjustments required for P-gp substrate Digoxin and the warning to avoid concurrent use of CYP2C9 substrate Warfarin with other drugs. Additionally, information on the dosage requirements for Prasugrel, R(+) enantiomer, and S(+) enantiomer for CYP2C8 substrate Rosigitazone are provided. Overall, this document serves as a tool for adjusting medication doses for their interactions with specific enzymes and substrates.*
Figure 5 - zontivity 06
The text describes the incidence rates, placebo and ZONTIVITY groups, and the results of a clinical trial. Not available information about the purpose and nature of the clinical trial.*
Figure 6 - zontivity 07
PRINCIPAL DISPLAY PANEL - 30 Tablet Bottle Label - zontivity 08
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.